INS-08055 is under clinical development by InSilico Medicine and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how INS-08055’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INS-08055 overview
InSilico Medicine overview
InSilico Medicine (InSilico) is a biotech company that primarily focuses on transforming drug discovery and development through generative artificial intelligence. The company’s main activities focus on leveraging its proprietary Pharma, AI platform to accelerate drug discovery and development across biology, chemistry, and clinical development. Its products include a fully self-generated AIDD pipeline primarily composed of novel drug candidates for various diseases such as ER+/HER2- breast cancer, kidney fibrosis, idiopathic pulmonary fibrosis, and several types of solid tumors. InSilico’s products are primarily used in the healthcare industry, specifically in the field of drug discovery and development. The company operates in the US, Canada, China, United Arab Emirates, Taiwan, and Hong Kong. InSilico is headquartered in Hong Kong city, Hong Kong.
For a complete picture of INS-08055’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.